Hokuriku Pharmaceutical announced that it plans to use its own capital of RMB 202 million to acquire 80% of Chengde Tianyuan Pharmaceutical's shares held by Jin'an Guoji and sign the “Equity Transfer Agreement on Chengde Tianyuan Pharmaceutical Co., Ltd.” with relevant shareholders of Tianyuan Pharmaceutical. After the acquisition is completed, Tianyuan Pharmaceutical will become a holding subsidiary of the company and will be included in the scope of the company's consolidated statements.
北陆药业：拟亿2.0亿元收购天原药业80%股权
Hokuriku Pharmaceutical: Plans to acquire 80% of Tianyuan Pharmaceutical's shares for 200 million yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.